Navigation Links
One cell type may quash tumor vaccines
Date:4/28/2014

(PHILADELPHIA) -- Most cancer vaccines have not lived up to their promise in clinical trials. The reason, many researchers suspect, is that the immune cells that would help the body destroy the tumor even those reactions boosted by cancer vaccines are actively suppressed. Now, researchers at Thomas Jefferson University have found that a single cell type is actively suppressed in several experimental cancer vaccines, paving the way toward methods to break suppression and improve the effectiveness of cancer vaccines. The work was published this week online in the European Journal of Immunology.

"The conventional wisdom is that the body knocks out all of the cells that can mount an immune response to the cancer," says first author Adam Snook, PhD, a Research Instructor at Thomas Jefferson University. "In fact, our work shows that it's only one cell type that is affected. But that cell, the T-helper cell, acts as the lynchpin."

Cancer vaccines are designed to boost the body's natural defenses against cancer. They work by training the immune system to recognize and attack specific tumor peptides, which are a kind of identification tag for tumors. These peptide "tags" help the immune system find and attack cancer cells. There are three types of cells that can "see" and react to these tags: T-helper cells, cytotoxic T cells, and B cells, and researchers thought that all three were trained, or tolerized, to ignore the tags on cancer cells.

Dr. Snook and colleagues tested which cell was involved by inoculating mice with a cancer vaccine they developed for colorectal cancer using a tumor peptide called guanylyl cyclase C (GUCY2C). Normally, GUCY2C-vaccinated mice would not produce much of an immune response, from either T cell type or B cells. However, when the researchers boosted the GUCY2C vaccine by linking it to another peptide called S1 that efficiently activates T-helper cells, they were able to see a vigorous activation of cytotoxic T cells and B cells directed at GUCY2C.

In fact, the GUCY2C vaccine-S1 combo improved the survival time of mice with cancer by months compared to only days with GUCY2C vaccine alone. In fact, many mice were cured of their disease.

When Dr. Snook tested two other cancer peptides, one for breast cancer (Her2) and one for melanoma (Trp2), he saw similar results, suggesting that selective inactivation of T helper cells occurs for peptides found in many cancer types. "The results make a lot of sense," says Dr. Snook. "T-helper cells, as their name suggests, provide help to both cytotoxic T cells and to B cells. The entire peptide-specific immune response can be taken out by tolerizing this one cell type."

In addition, T-helper cells are also essential for creating immunological memory. Boosting T-helper cell activation also protected mice from challenge with cancer months after the initial vaccination, increasing their survival and decreasing tumor number.

The next step is to test whether a T helper peptide-linked GUCY2C vaccine could help fight colorectal cancer in humans. Dr. Snook and colleagues are currently enrolling patients in a clinical trial aimed at reducing the rate of cancer recurrence in patients who had their primary tumors removed.


'/>"/>

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Researchers generate immunity against tumor vessel protein
2. 3D printing cancer tumors
3. Surprising new insights into the PTEN tumor suppressor gene
4. Finnish team of researchers finds a mutation in a tumor of the jaw
5. Scientists find key steps linking dietary fats and colon cancer tumor growth
6. Deep, integrated genomic analysis re-classifies lower-grade brain tumors
7. Prognosis of tumors positive for human papilloma virus in head and neck cancers varies according to the site
8. Adult cancer drugs show promise against an aggressive childhood brain tumor
9. New view of tumors evolution
10. Several FDA-approved anti-cancer drugs induce stem cell tumors, perhaps thwarting therapy
11. Going viral to target tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Colorado spine surgeon, ... of 334 spine surgeons to know in 2016 . The list consists of ... of spine surgery. , Dr. Corenman understands the importance of clinical excellence; he ...
(Date:2/11/2016)... ... ... The annual list showcases the 20 Most Promising SharePoint Solution Providers in ... commitment to the SharePoint ecosystem. A panel of experts and members of CIOReview’s editorial ... and promote technology entrepreneurship. , The survey was made at the end of ...
(Date:2/11/2016)... San Diego, CA (PRWEB) , ... February 11, 2016 , ... ... Combine which was held in San Diego, CA, on February 6th & 7th, 2016 ... NFL combine for those who were not invited to the NFL’s combine in Indianapolis,” ...
(Date:2/10/2016)... ... , ... President Obama’s budget proposal yesterday enables the HHS ... via telehealth, estimated to generate more than $160 million in savings over 10 ... Although there is more to be done, this represents an important victory ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... , a full-service health care communications company offering education, research and medical ... for practitioners and specialists working in infectious diseases. , As the all-inclusive ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 /PRNewswire/ ... a foot-focused suite of products designed to support ... ExoSOLS™, are custom orthotic insoles that combine years ... 1,000 partners in the podiatric field with cutting ... align, and propel . It is supported by ...
(Date:2/10/2016)... DUBLIN , February 11, 2016 /PRNewswire/ ... the addition of the "Molecular Diagnostics ... --> http://www.researchandmarkets.com/research/rp4pg8/molecular ) has announced ... Reports Bundle" report to their offering. ... http://www.researchandmarkets.com/research/rp4pg8/molecular ) has announced the addition of ...
(Date:2/10/2016)... och PITTSBURGH , ... lämnas inte, och detta pressmeddelande får inte ... eller till, och inga anmälningssedlar kommer att ... i, något land där Erbjudandet, distribution av ... Erbjudandet skulle strida mot tillämpliga lagar eller ...
Breaking Medicine Technology: